Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the efficacy and safety of mealtime or post‐meal fast‐acting insulin aspart (faster aspart) vs mealtime insulin aspart (IAsp), both in combination with insulin degludec, in participants with type 1 diabetes (T1D). Methods: This multicentre, treat‐to‐target trial (Clinical trial registry: NCT02500706, ClinicalTrials.gov ) randomized participants to double‐blind mealtime faster aspart ( n = 342) or IAsp ( n = 342) or open‐label post‐meal faster aspart ( n = 341). The primary endpoint was change from baseline in HbA1c 26 weeks post randomization. All available information, regardless of treatment discontinuation, was used for evaluation of the effect. Results: Non‐inferiority for the change from baseline in HbA1c was confirmed for mealtime and post‐meal faster aspart vs IAsp (estimated treatment difference [ETD]: 95%CI, −0.02% [−0.11; 0.07] and 0.10% [0.004; 0.19], respectively). Mealtime faster aspart was superior to IAsp for 1‐hour PPG increment using a meal test (ETD, −0.90 mmol/L [−1.36; –0.45]; P < 0.001). Self‐monitored 1‐hour PPG increment favoured faster aspart at breakfast (ETD, −0.58 mmol/L [−0.99; −0.17]; P = 0.006) and across all meals (−0.48 mmol/L [−0.74; −0.21]; P < 0.001). Safety profiles and overall rate of severe or blood glucose‐confirmed hypoglycaemia were similar between treatments, but significantly less hypoglycaemia was seen 3 to 4 hours after meals with mealtime faster aspart. Conclusion: Mealtime and post‐meal faster aspart in conjunction with insulin degludec provided effective glycaemic control compared with IAsp, with no increased safety risk. Mealtime faster aspart provided PPG control superior to that of IAsp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
Self-citationLane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C. T., Nielsen, T. S. S., Warren, M., Group Information, & 1, T. S. (2017) · JAMA · doi:10.1001/jama.2017.7115 · Cited by 206
Heise, T., Pieber, T. R., Danne, T., Erichsen, L., & Haahr, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0514-8 · Cited by 182
Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1771 · Cited by 177 · cited 14×
“Furthermore, the results here specifically support the results of the onset 1 study, in which once- or twice-daily detemir in conjunction with mealtime or post-meal faster aspart was compared with the same basal regimen and mealtime IAsp.(14) In the onset 1 study, however, there was a statistically significant differe…”
BackgroundMethodResultInfluentialSelf-citationBowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W. (2017) · Diabetes Care · doi:10.2337/dc16-1770 · Cited by 119 · cited 1×
“The improved PPG findings reported in the present study, from both meal test and SMBG, are consistent with general findings across the faster aspart clinical trial programme.(14,15,17,18) Furthermore, the results here specifically support the results of the onset 1 study, in which once- or twice-daily detemir in conju…”
ResultMathieu, C., Bode, B. W., Franek, E., Philis‐Tsimikas, A., Rose, L., Graungaard, T., Birk Østerskov, A., & Russell‐Jones, D. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13205 · Cited by 95
Self-citationFast-acting insulin aspart: the rationale for a new mealtime insulin
Evans, M., Wilkinson, M., & Giannpolou, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00685-0 · Cited by 23
Cited by
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Janež, A., Guja, C., Mitrakou, A., Lalic, N., Tankova, T., Czupryniak, L., Tabák, A. G., Prazny, M., Martinka, E., & Smircic-Duvnjak, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00743-7 · Cited by 177
Fast-acting insulin aspart: the rationale for a new mealtime insulin
Evans, M., Wilkinson, M., & Giannpolou, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00685-0 · Cited by 23
“26-week trial that evaluated FAsp as part of a basal-bolus regimen with insulin degludec [14].”
BackgroundMethodBowering, K., Harvey, J., Kolaczynski, J. W., Snyder, J. W., & Bode, B. W. (2019) · Diabetic Medicine · doi:10.1111/dme.13866 · Cited by 8
Metadata
- Authors
- Buse, J. B., Carlson, A. L., Komatsu, M., Mosenzon, O., Rose, L., Liang, B., Buchholtz, K., Horio, H., & Kadowaki, T.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-10-10
- Volume
- 20
- Issue
- 12
- Pages
- 2885-2893
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2893716860
- Cited by
- 56
- References
- 9
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial. https://app.cochat.ai/papers/10.1111/dom.13545
- The paper
- Buse, J. B., Carlson, A. L., Komatsu, M., Mosenzon, O., Rose, L., Liang, B., Buchholtz, K., Horio, H., & Kadowaki, T. (2018). Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13545
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.